“A Cost-Effectiveness Analysis of Sotorasib As Second-Line Treatment for Patients With KRAS-G12C-Mutated Metastatic Non-Small Cell Lung Cancer (mNSCLC) in Switzerland”. 2025. Swiss Medical Weekly 155 (1): 3777. https://doi.org/10.57187/s.3777.